Effects of different plasma substitutes on blood coagulation: A comparative review

Critical Care Medicine

Volumn 29, Issue 6, 2001, Pages 1261-1267

  De Jonge, Evert ^a,b   Levi, Marcel ^a,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Albumins; Blood coagulation; Blood coagulation disorders; Colloids; Dextrans; Gelatin; Hemorrhage; Hemostasis; Hetastarch; Plasma substitutes; Surgical blood loss

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 8; DEXTRAN; GELATIN; HETASTARCH; PLASMA SUBSTITUTE; VON WILLEBRAND FACTOR;

BLEEDING; BLOOD CLOTTING; COMPARATIVE STUDY; CRYSTALLOID; HEMOSTASIS; HUMAN; MEDICAL INFORMATION; MEDICAL LITERATURE; MOLECULAR WEIGHT; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVIEW;

EID: 0034990623     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200106000-00038     Document Type: Review

References (75)

1. Would the colloid detractors please sit down!
2. Crystalloids vs. colloids in fluid resuscitation: A systematic review
3. An international view of hydroxyethyl starches
4. Pharmacology and physiology of colloids
5. In vivo investigation into the effects of haemodilution with hydroxyethyl starch (200/0.5) and normal saline on coagulation
6. Clot formation and gelatin-based plasma substitutes
7. Clot formation and gelatin-based plasma substitutes
8. Modern aspects of prophylaxis and therapy for venous thrombo-embolic disease
9. Prevention of venous thromboembolism
10. Dextran prophylaxis of fatal pulmonary embolism
11. Effect of dextran on factor VIII (antihemophilic factor) and platelet function
12. The anti-thrombotic effect of dextran
13. Effect of dextran on factor VIII/von Willebrand factor structure and function
14. Dextran's anti-thrombotic properties in small arteries are not altered by low-molecular-weight heparin or the fibrinolytic inhibitor tranexamic acid: An experimental study
15. The effect of dextran 40 on patency following severe trauma in small arteries and veins
16. Plasma substitution with 3% dextran-60 in orthopaedic surgery: Influence on plasma colloid osmotic pressure, coagulation parameters, immunoglobulins and other plasma constituents
17. Effects of desmopressin acetate (DDAVP) and dextran on hemostatic and thromboprophylactic mechanisms
18. Effect of infusion of dextran 70 on fibrinolysis inhibition activity in human serum
19. Effect of dextran on fibrinolysis inhibition activity in the blood after major surgery
20. Effect of dextran on plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) during surgery
21. Volume replacement and coagulation: A comparative review
22. The effect of dextran 70 on the structure of plasma-derived fibrin gels
23. Effect of dextran on platelet activation by polymerizing fibrin
24. Do low molecular weight heparin and dextran increase the blood loss in transurethral resection of the prostate?
25. Prevention of fatal postoperative pulmonary embolism by heparin dihydroergotamine or Dextran 70
26. Low-molecular-weight heparin (enoxaparin) vs dextran 70: The prevention of postoperative deep vein thrombosis after total hip replacement
27. Thromboprophylaxis in patients with hip fractures: A prospective, randomized, comparative study between Org 10172 and dextran 70
28. Giving both enoxaparin and dextran increases the need for transfusion in revision hip arthroplasty
29. Clinical experience with 120,000 units of modified fluid gelatin
30. Reduced quality of clot formation with gelatin-based plasma substitutes
31. Haemodilution induces a hypercoagulable state
32. Gelatin use impairs platelet adhesion during cardiac surgery
33. Impaired haemostasis by intravenous administration of a gelatin-based plasma expander in human subjects
34. Use of modified fluid gelatin and hydroxyethyl starch for colloidal volume replacement in major orthopaedic surgery
35. Influence of different intravascular volume therapies on platelet function in patients undergoing cardiopulmonary bypass
36. Effects of 6% hydroxyethyl starch and 3% modified fluid gelatin on intravascular volume and coagulation during intraoperative hemodilution
37. Coagulopathy with the use of hetastarch in the treatment of vasospasm
38. Intraoperative hetastarch infusion impairs hemostasis after cardiac operations
39. A cluster of severe postoperative bleeding following open heart surgery
40. Hydroxyethyl starch induced acquired von Willebrand's disease
41. Severe coagulopathy in Jehovah's witness
42. Intracranial bleeding during treatment with hydroxyethyl starch
43. Hetastarch coagulopathy in a neurosurgical patient
44. A severe coagulopathy following volume replacement with hydroxyethyl starch in a Jehovah's Witness
45. Coagulation disorders caused by hydroxyethyl starch
46. Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII
47. Effect of hydroxyethyl starch and dextran on plasma volume and blood hemostasis and coagulation
48. Effect of hydroxyethyl starch on the activity of blood coagulation and fibrinolysis in healthy volunteers: Comparison with albumin
49. Hydroxyethyl starch as a prime for cardiopulmonary bypass: Effects of two different solutions on haemostasis
50. A study of haemostasis following the use of high doses of hydroxyethyl starch 120 and dextran in major laparotomies
51. Hemostatic effects of three colloid plasma substitutes for priming solution in cardiopulmonary bypass
52. Influence of hydroxyethyl starch on coagulation in patients during the perioperative period
53. The effects of desmopressin and 6% hydroxyethyl starch on factor VIII:C
54. The effect of 6% hydroxyethyl starch and desmopressin infusion on von Willebrand factor: Ristocetin co-factor activity
55. HES 200/0.5 is not HES 200/0.5. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics
56. All medium starches are not the same: Influence of the degree of hydroxyethyl substitution of hydroxyethyl starch on plasma volume, hemorrheologic conditions, and coagulation
57. No coagulation disorders under high-dose volume therapy with low-molecular-weight hydroxyethyl starch
58. Effects of hydroxyethyl starch on fibrinogen, fibrin clot formation, and fibrinolysis
59. Effects of pentastarch and albumin infusion on cardiorespiratory function and coagulation in patients with severe sepsis and systemic hypoperfusion
60. Pentastarch may cause fewer effects on coagulation than hetastarch
61. In vitro evaluation of the effect of profound haemodilution with hydroxyethyl starch 6%, modified fluid gelatin 4% and dextran 40 10% on coagulation profile measured by thromboelastography
62. Effect of progressive haemodilution with hydroxyethyl starch, gelatin and albumin on blood coagulation
63. Influence of different volume therapies on platelet function in the critically ill
64. On the inhibitory effect of albumin on platelet aggregation
65. Effect of increasing serum albumin on plasma D-dimer, von Willebrand factor, and platelet aggregation in CAPD patients
66. Highly substituted hydroxyethyl starch (HES200/0.62) leads to type-I von Willebrand syndrome after repeated administration
67. Comparison of hetastarch with albumin for postoperative volume expansion in children after cardiopulmonary bypass
68. Volume therapy in the critically ill: Is there a difference?
69. A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations
70. The safety and efficacy of ten percent pentastarch as a cardiopulmonary bypass priming solution. A randomized clinical trial
71. Large-dose administration of 6% hydroxyethyl starch 200/0.5 total hip arthroplasty: Plasma homeostasis, hemostasis, and renal function compared to use of 5% human albumin
72. Reduced quality of in-vitro clot formation with gelatin-based plasma substitutes
73. Compromised blood coagulation: An in vitro comparison of hydroxyethyl starch 130/0.4 and hydroxyethyl starch 200/0.5 using thrombelastography
74. Comparison of effects of Elohes and albumin on hemostasis in orthopedic surgery
75. Fluid resuscitation with Haemaccel vs. human albumin following coronary artery bypass grafting